The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
NCT07028632
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson Disease (PD)
Interventions
BIOLOGICAL:
Human Dopaminergic Progenitor Cells
Sponsor
iRegene Therapeutics Co., Ltd.